Off-label use of risperidone in people with intellectual disability: A discontinuation study
Not yet recruiting
- Conditions
- challenging behaviorintellectual disabilityoff-label risperidoneoff-label antipsychotics
- Registration Number
- NL-OMON27969
- Lead Sponsor
- niversity Medical Center Groningen (UMCG)
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending
- Sex
- Not specified
- Target Recruitment
- 100
Inclusion Criteria
1. IQ<70 as assessed by an authorized behavioral therapist
2. Age > 6 years
Exclusion Criteria
1. A history of schizophrenia, a bipolar disorder, or affective psychosis according to DSM IV or ICD-10 criteria
2. A history of unsuccessful withdrawal of antipsychotics in the past 6 months
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Behavior measured by the irritability subscale of the Aberrant Behavior Checklist (ABC)
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie risperidone's efficacy in managing challenging behaviors in intellectual disability?
How does off-label risperidone compare to standard-of-care antipsychotics for intellectual disability-related behavioral issues?
Are there specific biomarkers that predict response to risperidone discontinuation in individuals with intellectual disability?
What are the known adverse events associated with long-term off-label risperidone use in intellectual disability populations?
What alternative antipsychotic drugs or combination therapies are being explored for challenging behaviors in intellectual disability?